 |
 |
 |
  |
|
 |
PRESS RELEASES |
 |
|
|
= Add Release to Briefcase |
| All Releases |
 |
Savient Pharmaceuticals Reports Second Quarter 2008 Financial Results
08-06-08
|
20.5 KB
|
| |
EAST BRUNSWICK, N.J., Aug 06, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three and six months ended June 30, 2008. The net loss for the second quarter of 2008 was $24.2 million or $0.45 per basic and diluted share on total revenues of $0.4 million, compared with a net loss of $9.6 m...
|
|
 |
Savient Pharmaceuticals to Hold Second Quarter Financial Results Conference Call on Thursday, August 7, 2008
07-28-08
|
9.0 KB
|
| |
EAST BRUNSWICK, N.J., Jul 28, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the company will release financial results for the second quarter 2008 following the close of the market on Wednesday, August 6, 2008.
Christopher Clement, President and Chief Executive Officer, and Brian Hayden, Senior Vice P...
|
|
 |
Savient Announces U.S. Court of Appeals Affirmation of the Dismissal of Securities Class Action Complaint
07-03-08
|
8.5 KB
|
| |
EAST BRUNSWICK, N.J., Jul 03, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today announced that the United States Court of Appeals for the Third Circuit has entered a Judgment affirming the decision of the U.S. District Court for the District of New Jersey dismissing, with prejudice, the Second Consolidated Amended Complaint ...
|
|
 |
Savient Pharmaceuticals to Present At Jefferies 2nd Annual Healthcare Conference On June 26th
06-17-08
|
9.1 KB
|
| |
EAST BRUNSWICK, N.J., Jun 17, 2008 (PrimeNewswire via COMTEX News Network) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) today announced that Christopher Clement, President and Chief Executive Officer of Savient Pharmaceuticals will present a corporate update at the upcoming Jefferies 2nd Annual Healthcare Conference.
The presentation is sched...
|
|
 |
Christopher G. Clement, President and CEO of Savient Pharmaceuticals, Named Ernst & Young Entrepreneur of The Year 2008 Award Finalist in New Jersey
06-09-08
|
11.4 KB
|
| |
EAST BRUNSWICK, N.J., Jun 9, 2008 (PrimeNewswire via COMTEX News Network) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) today announced that President and CEO Christopher G. Clement is a finalist for The New Jersey Ernst & Young Entrepreneur Of The Year(r) 2008 Awards. According to Ernst & Young LLP, the awards program recognizes entrepren...
|
|
 |
Savient Pharmaceuticals to Present At Citi Investment Research Global Healthcare Conference On May 22nd
05-13-08
|
9.1 KB
|
| |
EAST BRUNSWICK, N.J., May 13, 2008 (PrimeNewswire via COMTEX News Network) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) today announced that Paul Hamelin, Senior Vice President, Commercial Operations of Savient Pharmaceuticals will present a corporate update at the upcoming Citi Investment Research Global Healthcare Conference.
The presentati...
|
|
 |
Savient Pharmaceuticals Reports First Quarter 2008 Financial Results
05-07-08
|
17.5 KB
|
| |
EAST BRUNSWICK, N.J., May 07, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today reported financial results for the three months ended March 31, 2008. The net loss for the first quarter of 2008 was $17.6 million or $0.33 per share on total revenues of $1.2 million, compared with a net loss of $7.8 million or $0.15 per share o...
|
|
 |
Savient Reports Favorable Interim Data from Puricase(R) (pegloticase) Open Label Extension Study
05-07-08
|
16.3 KB
|
| |
EAST BRUNSWICK, N.J., May 07, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), today announced positive interim data from the ongoing pegloticase open label extension (OLE) to the Phase 3 pivotal trials in patients with treatment-failure gout. The interim results are based on the OLE data cut at the end of September 2007.
T...
|
|
 |
Savient Pharmaceuticals to Present at Deutsche Bank Securities 33rd Annual Healthcare Conference on May 5th
04-21-08
|
8.5 KB
|
| |
EAST BRUNSWICK, N.J. (April 21 , 2008) - Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Christopher Clement, President and Chief Executive Officer of Savient Pharmaceuticals, will present a corporate update at the upcoming Deutsche Bank Securities 33rd Annual Healthcare Conference.
The presentation is scheduled ...
|
|
 |
Savient Provides Update On Puricase(R) (pegloticase) Biologics License Application
04-21-08
|
13.7 KB
|
| |
EAST BRUNSWICK, N.J., Apr 21, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today announced an update on plans for filing its Biologics License Application (BLA) for Puricase(R) (pegloticase) for treatment-failure gout based on the results of its pre-BLA meeting with the U.S. Food and Drug Administration (FDA) reviewing divisi...
|
|
 |
Savient Pharmaceuticals to Hold First Quarter 2008 Financial Results Conference Call On Thursday, May 8, 2008
04-16-08
|
9.3 KB
|
| |
EAST BRUNSWICK, N.J., Apr 16, 2008 (PrimeNewswire via COMTEX News Network) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) announced today that the company will release financial results for the first quarter 2008 following the close of the market on Wednesday, May 7, 2008.
Christopher Clement, President and Chief Executive Officer, and Brian Ha...
|
|
 |
Savient Pharmaceuticals to Present at 28th Annual Cowen Healthcare Conference on March 18
03-12-08
|
8.7 KB
|
| |
EAST BRUNSWICK, N.J., Mar 12, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today announced that Paul Hamelin, Senior Vice President, Commercial Operations of Savient Pharmaceuticals will present a corporate update at the upcoming 28th Annual Cowen Healthcare Conference.
The presentation is scheduled to begin at 10:15 a.m....
|
|
 |
Savient Pharmaceuticals Reports Fourth Quarter and Year End 2007 Financial Results
03-11-08
|
19.3 KB
|
| |
EAST BRUNSWICK, N.J., Mar 11, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today reported financial results for the three months and year ended December 31, 2007. For the fourth quarter of 2007, the Company had a net loss of $16.6 million, or $0.31 per share, on total revenues of $1.9 million. For the year ended December 31, ...
|
|
 |
Savient Provides Further Information on Top Line Phase 3 Trials Results for Puricase(R) (pegloticase)
02-28-08
|
12.7 KB
|
| |
EAST BRUNSWICK, N.J., Feb 28, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced further information related to infusion reactions and deaths for their Phase 3 clinical trials for Puricase(R) (pegloticase) being developed for treatment failure gout patients.
Severe and Serious Infusion Reactions
Our prelimi...
|
|
 |
Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2007 Financial Results Conference Call on Wednesday, March 12, 2008
02-15-08
|
9.0 KB
|
| |
EAST BRUNSWICK, N.J., Feb 15, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) announced today that the company will release financial results for the fourth quarter and year-end 2007 following the close of the market on Tuesday, March 11, 2008.
Christopher Clement, President and Chief Executive Officer, and Brian Hayden, Chi...
|
|
 |
Savient Reports Additional Positive Trial Data for Secondary Endpoints from Puricase(R) (pegloticase) Phase 3 Studies
02-04-08
|
15.8 KB
|
| |
EAST BRUNSWICK, N.J., Feb 04, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT), today announced additional positive results for secondary efficacy endpoints in the two replicate Phase 3 studies for Puricase(R) (pegloticase) for treatment-failure gout. Results were favorable for the treatment effect on clinical outcomes assessed b...
|
|
 |
Savient to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
01-22-08
|
8.7 KB
|
| |
EAST BRUNSWICK, N.J., Jan 22, 2008 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Christopher G. Clement, President and Chief Executive Officer, and Zeb Horowitz M.D., Chief Medical Officer of Savient Pharmaceuticals, will present a corporate update at the upcoming 2008 Merrill Lynch Global Pharmaceutical, Biot...
|
|
 |
Savient Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
12-17-07
|
9.2 KB
|
| |
EAST BRUNSWICK, N.J., Dec 17, 2007 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today announced that Christopher G. Clement, President and Chief Executive Officer and Zeb Horowitz M.D., Chief Medical Officer of Savient Pharmaceuticals will present a corporate update at the upcoming 26th Annual JP Morgan Healthcare Conference.
...
|
|
 |
Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies
12-13-07
|
20.2 KB
|
| |
EAST BRUNSWICK, N.J., Dec 13, 2007 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) is pleased to announce statistically significant positive results for the Puricase (pegloticase) Phase 3 program in treatment-failure gout patients, which has been conducted under the auspices of a Special Protocol Assessment (SPA) with the U.S. Food a...
|
|
 |
Savient Pharmaceuticals to Release Top-Line Results from Puricase(R) Phase 3 Trials in Treatment-Failure Gout on December 13, 2007
12-12-07
|
9.5 KB
|
| |
EAST BRUNSWICK, N.J., Dec 12, 2007 (BUSINESS WIRE) -- Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) announces that the Company will make public top-line results from its two pivotal Phase 3 clinical trials with Puricase(R) (pegloticase) for patients with treatment-failure gout via a news release to be issued at approximately 6:00 a.m. eastern time on...
|
|
|
|
|
Savient Pharmaceuticals, Inc. (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.
The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.
|
  |
 |
Copyright © 2008 Savient Pharmaceuticals, Inc. All rights reserved. |
|
 |